Prothena News

Express News | Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Moomoo 24/7Apr 15 16:05 ET

Cantor Fitzgerald Reiterates Overweight on Prothena Corp

Cantor Fitzgerald analyst Charles Duncan reiterates Prothena Corp (NASDAQ:PRTA) with a Overweight.

BenzingaApr 10 13:26 ET

Despite Shrinking by US$81m in the Past Week, Prothena (NASDAQ:PRTA) Shareholders Are Still up 108% Over 5 Years

Some Prothena Corporation plc (NASDAQ:PRTA) shareholders are probably rather concerned to see the share price fall 43% over the last three months. But that doesn't change the fact that the returns

Simply Wall StApr 5 07:25 ET

Labcorp Expands Alzheimer's Testing Portfolio With New Diagnostic

Seeking AlphaMar 20 09:00 ET

Demystifying Prothena Corp: Insights From 8 Analyst Reviews

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Prothena Corp (NASDAQ:PRTA) in the last three months.Summarizing their recent assessments, the t

BenzingaMar 13 10:00 ET

Prothena Is Maintained at Buy by HC Wainwright & Co.

Prothena Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 13 09:36 ET

Express News | HC Wainwright & Co. Maintains Buy on Prothena Corp, Maintains $90 Price Target

Moomoo 24/7Mar 13 09:25 ET

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Belite Bio, Inc. ADR (BLTE) and Prothena (PRTA)

TipRanksMar 13 06:20 ET

Piper Sandler Reaffirms Their Buy Rating on Prothena (PRTA)

TipRanksMar 7 07:36 ET

Prothena to Participate in Upcoming Healthcare Conferences

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its

BusinesswireMar 5 16:05 ET

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has named

BusinesswireMar 4 16:05 ET

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan

BenzingaFeb 29 12:35 ET

Prothena Files to Offer Ordinary Shares

Seeking AlphaFeb 22 17:44 ET

Prothena Appoints Daniel G. Welch as Chair Designate

Seeking AlphaFeb 21 16:22 ET

Prothena Is Maintained at Outperform by Oppenheimer

Prothena Is Maintained at Outperform by Oppenheimer

Dow JonesFeb 20 09:16 ET

Oppenheimer Cuts Prothena Price Target to $80 From $98, Maintains Outperform Rating

Prothena (PRTA) has an average rating of Outperform and price targets ranging from $35 to $94, according to analysts polled by Capital IQ. Price: 27.5, Change: -0.52, Percent Change: -1.86

MT NewswiresFeb 20 08:42 ET

Buy Rating Affirmed on Prothena Amid Strong Pipeline Progress and Solid Financials

TipRanksFeb 18 23:45 ET

Express News | JMP Securities Maintains Market Outperform on Prothena Corp, Raises Price Target to $85

Moomoo 24/7Feb 16 14:58 ET

Decoding 6 Analyst Evaluations For Prothena Corp

In the latest quarter, 6 analysts provided ratings for Prothena Corp (NASDAQ:PRTA), showcasing a mix of bullish and bearish perspectives.Summarizing their recent assessments, the table below illustrat

BenzingaFeb 16 14:00 ET

Prothena Is Maintained at Sector Perform by RBC Capital

Prothena Is Maintained at Sector Perform by RBC Capital

Dow JonesFeb 16 12:55 ET